|
May 30
|
3 Cash-Burning Stocks Facing Headwinds
|
|
May 27
|
Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025
|
|
May 27
|
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
|
|
May 27
|
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
|
|
May 22
|
3 Small-Cap Stocks with Questionable Fundamentals
|
|
May 21
|
Spotlight On 3 Penny Stocks With Market Caps Under $500M
|
|
May 19
|
MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp
|
|
Apr 15
|
Myriad Genetics price target lowered to $9 from $11 at BofA
|
|
Apr 8
|
Myriad Genetics Announces Inducement Awards
|
|
Apr 7
|
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
|
|
Mar 12
|
Why Are Myriad Genetics (MYGN) Shares Soaring Today
|
|
Mar 11
|
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
|
|
Feb 27
|
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
|
|
Feb 26
|
Myriad Genetics Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 25
|
Why Myriad Genetics (MYGN) Shares Are Plunging Today
|
|
Feb 25
|
Myriad Genetics, Inc. (MYGN): AI-Driven Precision Medicine for Prostate Cancer
|
|
Feb 25
|
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
|
|
Feb 25
|
Q4 2024 Myriad Genetics Inc Earnings Call
|
|
Feb 25
|
Myriad Genetics Inc (MYGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
|
Feb 24
|
Myriad: Q4 Earnings Snapshot
|